New Combination Builds Upon Existing Therapies for Anaplastic Astrocytoma

February 1, 2020
Arati Desai, MD

Arati Desai, MD, explains how the results from the phase III STELLAR trial will enhance knowledge of anaplastic astrocytoma.

Arati Desai, MD, co-director of the University of Pennsylvania Brain Tumor Cancer Program Center and assistant professor of Clinical Medicine, at the Perelman School of Medicine, University of Pennsylvania, explains how the results from the phase III STELLAR trial will enhance knowledge of anaplastic astrocytoma (AA).

When treatment advances are sought, the therapies that are needed are those that improve upon the standard of care. There are good agents available for the treatment of AA, but the drugs are older and, at times, cause intolerable toxicity and offer limited benefit.